Regeneron Pharmaceuticals (REGN) Jefferies Global Healthcare Conference summary

Oncology program updates

• PD-1/LAG-3 program shows promising melanoma data, with phase III readout expected in the coming year and early NSCLC data anticipated by year-end.

• Differentiation in efficacy is observed not just by target but by the specific antibody, with optimism for broader applicability beyond biomarker-driven subpopulations.

• Durable responses and improved progression-free survival are emerging in melanoma, with a head-to-head study versus Opdualag underway.

• LAG-3's benefit is most pronounced in first-line settings, with ongoing studies in adjuvant and perioperative contexts for melanoma and NSCLC.

• CD28 bispecifics, including EGFR and PSMA combinations, demonstrate efficacy in solid tumors and prostate cancer, with efforts to decouple efficacy from toxicity.

Hematology and other pipeline highlights

• Systemic C5 inhibition for geographic atrophy (GA) leverages siRNA and antibody to target liver-produced C5, aiming for bilateral disease control and reduced local injection risks.

• Patient selection and mitigation strategies are prioritized to manage infection risks in systemic GA therapy, with the approach offering advantages over intravitreal injections.

• Factor XI antibody program offers higher target inhibition than oral agents, with two differentiated antibodies in proof-of-concept studies and readouts expected by year-end.

• Preclinical data suggest superior efficacy and risk-benefit profile for Factor XI antibodies, with potential for use in specific clinical settings.

Industry context and forward-looking statements

• Oncology faces challenges with therapeutic windows and immune exhaustion, but new combinatorial and bispecific approaches are being actively explored.

• Forward-looking statements are subject to risks and uncertainties as outlined in SEC filings.